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Glycodendritic structures: tools to 
interact with DC-SIGN
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The key role of carbohydrates in many biological events has attracted the interest of 
the scientific community. This fact has demanded the access to new tools necessary to 
understand this role and the interaction of carbohydrates with their corresponding receptors, 
lectins. Glycodendrimers and glycodendritic structures in general, have demonstrated to 
be very efficient and interesting tools to intervene in those processes where carbohydrates 
participate. In this review, we discuss the different glycodendritic structures that have been 
used to interfere with DC-SIGN, a very attractive lectin involved in infection processes 
and in the regulation of the immune response.
Uniterms: DC-SIGN. Ebola. Glycodendrimers. Glycofullerenes. HIV. Mannose.
O papel chave dos carboidratos em muitos eventos biológicos tem atraído interesse 
da comunidade científica. Este fato demonstrou o acesso de novas ferramentas para a 
compreensão da interação dos carboidratos com seus receptores correspondentes, lectinas. 
Glicodendrímeros e estruturas glicodendríticas, em geral, mostram-se como ferramentas 
muito eficientes e interessantes para intervir nos processos em que os carboidratos 
participam. Nesta revisão, discutimos diferentes estruturas glicodendríticas que têm sido 
úteis para interferir com DC-SIGN, uma lectina muito atraente envolvida em processos 
infecciosos e na regulação da resposta imune.
Unitermos: DC-SIGN. Ebola. Glicodendrímeros. Glicofulerenos. HIV. Manose.
INTRODUCTION
Glycans are not only an important source of metabolic energy; they 
are also widely expressed as glycoconjugates on the surface of cells where 
they play a key role in many important biological processes (Varki, 1993; 
Kamerling 2007; Werz, Seeberger, 2007). In the past decade, the increased 
appreciation for the ubiquity of glycans and their ability to encode bio-
chemical information has given rise to the field of glycobiology (Varki, 
1999; Bertozzi, Kiessling, 2001) with the aim to explain and understand 
how chemical information is encode in sugar structures and how this infor-
mation is read out by sugar binding proteins (lectins) (Gabius et al., 2011; 
Gupta, Surolia, 2012). Lectins are proteins that recognize glycans (glyco-
lipids and glycoproteins) with high specificity, and this carbohydrate-lectin 
interaction is implicated in several important biological events such as 
cell-cell self-recognition processes, cell-extracellular matrix interaction, 
gamete fertilization, embryonic development, cell growth, cell differen-
tiation, cell signaling, cell adhesion and migration, apoptosis, immuno-
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modulation and inflammation, host-pathogen interactions, 
glycoprotein folding and routing, mitogenic induction and 
homeostasis (Varki, 1993; Weis, 1998; Sharon, Lis, 2004; 
Ghazarian, 2011). Thus, in principle, lectins can clearly be 
considered as potential targets for the development of new 
drugs. However, they have rarely been exploited for the 
discovery of novel therapeutic opportunities. Frequently, 
medicinal chemists have mostly disregarded carbohy-
drates as a class of molecules for drug development, basi-
cally due to their poor drug-like properties including their 
low stability and their high polar character.
Carbohydrate-protein (carbohydrate-lectin) inter-
actions are characterized by a high selectivity, metal ion 
dependence, and a low affinity compensated in nature by 
a multivalent presentation of glycans and receptors (Lee, 
Lee, 1995; Chabre, Roy, 2010). The carbohydrate recogni-
tion domains (CRD) of lectins are often able to recognize 
complex oligosaccharides in a selective manner; however, 
the recognized oligosaccharide determinants often consist 
of only one or two residues, usually located in the non-
reducing end of the oligosaccharide structure, that appear 
to act as anchors, driving the entire glycoconjugate to 
interact with the protein. The most abundant animal lectins 
are the C-type lectins (CTL) (Kilpatrick, 2000), that in 
most of the cases are large, asymmetric trans-membrane 
glycoproteins, with one or more CRDs attached to a vari-
able number of structurally and functionally different 
polypeptide domains.
The interaction between sugars and lectins is driven 
by hydrogen bonds, coordination of monosaccharide resi-
dues with metals (for C-type lectins and related calcium-
dependent proteins), ionic and hydrophobic interactions, 
that all contribute to the binding affinity (Weiss, Drickamer, 
1996). The energy associated with hydrogen bonding 
in sugar–protein interactions is significantly reduced by 
competition from bulk solvent and by the flexible nature 
of hydroxyl groups, which results in a considerable entro-
pic penalty when they become constrained upon binding. 
Sugar CH bonds can engage in stacking interactions with 
protein aromatic side chains, but natural carbohydrates 
usually lack extended hydrophobic areas, often a domi-
nant factor in high-affinity receptor–ligand interactions. 
Hence, the affinity of lectins for monovalent carbohydrates 
is typically weak (dissociation constants are in the mM 
to μM range). However, most lectins are multimeric and, 
therefore, polyvalent presentations of monosaccharides 
acting as binding determinants for a given lectin can be 
used for inhibition, increasing the affinity in comparison 
with the corresponding monovalent ligands (Mammen, 
1998; Culf, 2006; Turnbull, Field, 2007). For this aim, a 
vast array of unnatural glycoconjugates (neoglycoconju-
gates) with different valencies and spatial arrangement of 
the ligand have been constructed as sugar binding proteins 
antagonist to prevent or treat diseases caused by pathogens 
(Bernardi et al., 2013). Scaffolds based on peptides and 
proteins (Davis, 2002; Payne, Wong, 2010; Westerlind, 
2012), polymers (Miura, 2012; Eissa, Cameron, 2013), 
calixarenes (Baldini, et al., 2007; Dondoni, Marra, 2010), 
dendrimers (Li, Cheng, Xu, 2007; Chabre, Roy, 2008), 
cyclodextrins (Fulton, Stoddart, 2001; Gomez-Garcia, 
2012; Martínez, Ortíz Mellet, García Fernández, 2013), 
cyclopeptides (Galan, Dumy, Renaudet, 2013), fullerenes 
(Nierengarten, 2010), gold nanoparticles and quantum 
dots (El-Boubbou, 2011; Marradi et al., 2013) provide 
nanoscale materials with anti-adhesive and cell targeting 
properties.
In our research group, we are interested in a specific 
lectin named DC-SIGN, a C-type lectin able to recognize 
and interact with a number of highly glycosylated proteins 
presented in the surface of a diverse group of pathogens 
(Van Kooyk, Geijtenbeek, 2003). The broad pathogen 
spectrum that could use DC-SIGN during the infection 
process places this lectin as an important target in infec-
tion diseases. In the present review, we will describe 
the approaches to design and synthesize glycodendritic 
antagonist for DC-SIGN.
DC-SIGN
DC-SIGN (Dendritic cell-specific ICAM-3 grabbing 
nonintegrin, CD209) was originally defined as an intercel-
lular adhesion molecule-3 (ICAM-3) receptor that play an 
important role in establishing the first contacts between 
dendritic cells (DCs) and resting T cells (Geijtenbeek et 
al., 2000). It is a type II trans-membrane C-type lectin with 
a single C-terminal Carbohydrate Recognition Domain 
(CRD). In the cellular membrane, DC-SIGN is assembled 
as a tetramer, due to an extended coiled-coil region that 
allows simultaneous presentation of four CRDs (Mitchell 
et al., 2001; Feinberg et al., 2005; Serrano-Sierra-Gomez 
et al., 2008; Tabarani et al., 2009).
DC-SIGN is one of the dendritic cells specific patho-
gen-uptake receptors and recognizes glycoconjugates on 
the surface of several pathogens, including viruses (HIV, 
Ebola, Cytomegalovirus, Dengue, SARS), bacteria (M. tu-
berculosis, S. pneumoniae), fungi (C. albicans, A. fumiga-
tus), and parasites (Leishmania, S. mansoni) (Van Kooyk, 
Geijtenbeek, 2003). It has been proven that this lectin plays 
a key role in the initial steps of infections caused by some 
of these pathogens. In particular, DC-SIGN was brought 
to attention by the group of van Kooyk, who reported that 
HIV-1 targets DC-SIGN, but escapes degradation in lytic 
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compartments, thus using DCs as a Trojan horse to invade 
the host organism (Geijtenbeek et al., 2000a). Inhibition 
of DC-SIGN is currently considered as an interesting ap-
proach for the design of new anti-infective agents (Reina et 
al., 2010; Sánchez-Navarro, Rojo, 2010; Reina, Bernardi, 
2012). The detailed molecular mechanism by which this 
receptor operates is not fully understood, thus effective 
modulators of DC-SIGN are also needed to unravel the 
different biological processes in which this receptor is 
involved. The main carbohydrate ligand recognized by 
DC-SIGN is the high mannose glycan, (Man)9(GlcNAc)2, 
(Figure 1) a branched oligosaccharide presented in mul-
tiple copies by several pathogen glycoproteins and specifi-
cally by the gp120 envelope protein of HIV. DC-SIGN can 
also recognize branched fucosylated structures bearing 
terminal fucose residues, such as the Lewis antigens.
The primary interaction of oligosaccharides and 
DC-SIGN occurs by coordination of a residue of the oligo-
saccharide (often the non-reducing end) to a Ca2+ binding 
site exposed to the surface of the protein (Feinberg et al., 
2001; Guo et al., 2004; Feinberg et al., 2007). X-ray data 
are available for complexes of the DC-SIGN carbohydrate 
recognition domain (CRD) with both mannose oligosac-
charides and Lewis-X (Feinberg et al., 2001; Guo et al., 
2004; Feinberg et al., 2007). Besides the role that DC-
SIGN plays in infection processes, the recent discovery 
of DC-SIGN as a lectin involved in immunoregulation 
processes attracted the interest of many scientists due to 
the possibility to exploit this lectin as a new potential target 
in immunotherapy. This important discovery has opened 
the possibility to design specific carbohydrate multivalent 
systems to modulate the immune response through the 
interaction with DC-SIGN. This is a field of tremendous 
interest and very active research is ongoing in this area 




Highly mannosylated polyvalent compounds have 
been developed in an effort to target DC-SIGN mediated 
viral transmission. This topic has been recently reviewed 
(Sánchez-Navarro, Rojo, 2010) and therefore, only two 
representative examples, one based on gold nanoparticles 
and another one based on a polymer scaffold have been 
selected to be highlighted in the present review.
Penadés and Alcami have reported a remarkable 
example using gold nanoparticles (GNP) displaying differ-
ent mannosyl oligosaccharides (Manno-GNPs) as potent 
inhibitors of DC-SIGN mediated HIV trans-infection of 
human activated peripheral blood mono-nuclear cells 
(Martinez-Avila et al., 2009). The selected ligands were 
linear and branched oligosaccharides containing one to 
seven mannose units. Using Biosensors with Surface 
Plasmon Resonance (SPR) detection it was demonstrated 
that these GNPs were very good inhibitors in a competi-
tive study using DC-SIGN and gp120 (Hijazi, 2009). In 
particular, the GNPs functionalized with the linear disac-
charide Manalpha1-2Man was the best inhibitor showed a 
FIGURE 1 - Cartoon of DC-SIGN and chemical structure of Lewis X and (Man)9(GlcNAc)2 glycans.
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20,000-fold increased activity in comparison with the cor-
responding monovalent ligand. It was also demonstrated 
that the maximum activity was achieved with 50% surface 
density. A selection of GNPs was tested in in vitro HIV-1 
infection studies using viruses with different tropism (Mar-
tinez-Avila et al., 2009). The experiments demonstrated 
that these GNPs were able to inhibit the trans-infection of 
T cells at very low concentrations. In particular, the GNP 
with 56 copies of a linear tetrasaccharide at a density of 
50% (Figure 2) was the most potent inhibitor with an IC50 
in the low nanomolar range. This is the first example where 
a carbohydrate multivalent system has been tested in in 
vitro HIV infection studies successfully.
Another approach to prepare DC-SIGN inhibitors 
was described by the group of Kiessling, who used a 
shikimic acid-derived glycomimetic scaffold of general 
formula A (Schuster et al., 2003; Gaber et al., 2010). (Fig-
ure 3). The shikimic acid derivative prepared by Kiessling 
and co-workers shared the same hydroxyl arrangement as 
mannose at positions 2, 3 and 4, and could be considered 
as a good mimetic of mannose for lectin recognition. In 
addition to the hydroxyl groups that mimic mannose, this 
shikimic acid derivative presented two possible points of 
diversification, a carboxylic group and a thiol that were 
exploited to introduce different substituents and to syn-
thesize a library of 192 compounds. All these compounds 
were tested using a fluorescence-based high-throughput 
competition assay that assessed their ability to compete 
with immobilized mannan for binding the fluorophore-
labeled extracellular domain of DC-SIGN. The best 
compound of the library was B, (Figure 3) which had an 
IC50 of 11.2 mM, but was found to be more selective for 
DC-SIGN than for mannose-binding protein A (MBP-A). 
A multivalent presentation of compound B was prepared 
by ring-opening metathesis polymerization (ROMP) 
(Bielawski, Grubbs, 2007). The final glycopolymer was 
1000-fold more potent than the monomeric inhibitor, the 
compound B.
GLYCODENDRIMERS TARGETING DC-SIGN
There are several precedents where dendrimers have 
been used as scaffolds to achieve a multivalent presenta-
tion of carbohydrates, the so called glycodendrimers. 
Furthemore, it have been observed that these kind of 
FIGURE 2 - Gold glyconanoparticle with 50% of glucose and 
50% of a linear tetrasaccharide.
FIGURE 3 - Shikimic-based derivatives as ligands for DC-SIGN.
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carbohydrates multivalent systems are important tools to 
interfere in biological processes where lectins or sugar 
binding proteins are implicated (Roy, 1996; Turnbull, 
Stoddart, 2002; von der Lieth, Frank, Lindhorst, 2002; 
Roy, Baek, 2002; Bezouška, 2002; Roy, 2003; Li, Cheng, 
Xu, 2007; Chabre, Roy, 2008, 2010; Sánchez-Navarro, 
Rojo, 2010).
Among them, a recent interesting example where 
a glycodendron was used to interact with DC-SIGN was 
described by Wong and co-workers. They have reported 
oligomannose dendrons which display 3, 9 and 27 copies 
of complex oligomannoses (Figure 4) in high density as in-
hibitors of gp120 binding to recombinant dimeric DC-SIGN 
(Wang et al., 2008). The selected carbohydrates were a 
linear tetramannosyl ligand (Man4) corresponding to the D1 
arm of high mannose and a branched nanomannosyl oligo-
saccharide that represented the high mannose glycan (Figure 
1). In a competition experiment using gp120 as a ligand for 
DC-SIGN, it was demonstrated that these glycodendrons 
inhibited the binding between gp120 and DC-SIGN with 
an IC50 of 20 and 8 nM for compounds with nine copies of 
Man4 and nine copies of Man9, respectively.
Since almost a decade ago, our group is interested 
in the design and synthesis of different multivalent com-
pounds based on mannose and glycomimetics of high 
mannose oligosaccharides and Lewis-X, as potential 
molecules able to block the binding of pathogen envelope 
glycoproteins to DC-SIGN. For this aim, we focused on 
dendrimers and dendritic structures as appropriate scaf-
FIGURE 4 - Glycodendrons with 27 copies of Man4 and Man9.
folds for a multivalent presentation of carbohydrates 
trying to achieve binding affinities to DC-SIGN in the 
mM to nM range, a task without precedents at that time. 
In this revision article, we will give and overview of the 
work performed in our group related with glycodendritic 
structures as DC-SIGN antagonist.
Boltorn-type glycodendritic structures
As a proof of concept, we addressed a divergent 
approach (Fréchet, Tomalia, 2001; Newkome, Moore-
field, Vögtle, 2001; Sánchez-Navarro, Rojo, 2012) to 
synthesize glycodendrimers using very simple and ac-
cessible molecules. We selected a Boltorn hyperbranched 
dendritic polymer, commercially available at a very low 
price, as scaffold and a simple monosaccharide, man-
nose, as ligand to DC-SIGN to be conjugated on it. These 
hyperbranched polymers have been constructed using 
bis-hydroxymethylpropionic acid (Bis-MPA) as build-
ing block and pentaerythritol as core. The glycodendritic 
polymers were prepared using the 2nd and 3rd generation 
of Boltorn dendritic polymers conjugated with 16 and 32 
mannoses, respectively. (Figure 5). We demonstrated that 
these glycodendritic structures were perfectly soluble in 
physiological conditions, non-toxic against several cell 
lines and easy to be prepared (Arce et al., 2003).
The affinity of these glycodendritic polymers to DC-
SIGN was evaluated using a SPR biosensor (Tabarani et 
al., 2006). Experiments clearly shown that the binding of 
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BH30sucMan based on BH30 (3rd generation of Boltorn) 
to DC-SIGN was calcium and carbohydrate dependent and 
therefore should take place through the carbohydrate rec-
ognition domain of the lectin. An apparent affinity in the 
sub microMolar range was found (3 orders of magnitude 
increase in comparison with the monovalent mannose). 
Using SPR, we also set up a competition experiment assay 
in which different glycodendritic structures were analyzed 
for their ability to inhibit the gp120/DC-SIGN interaction, 
finding an IC50 of 50 µM for BH30sucMan. Additionally, it 
was demonstrated the antiviral properties of the mannosyl 
glycodendritic structure BH30sucMan using an Ebola 
Virus infection model. This glycodendritic hyperbranched 
polymer inhibited DC-SIGN-mediated Ebola Virus infec-
tion in cis and in trans (Lasala et al., 2003; Rojo, Delgado, 
2004). The experiment showed that BH30sucMan was 
able to selectively inhibit direct DC-SIGN-mediated Ebola 
infection in an efficient dose-dependent manner (IC50 337 
nM). In the experiment in trans, in which a more complex 
series of events such as internalization and presentation 
of the viral particle to susceptible cells can take place, 
BH30sucMan also showed a significant reduction of DC-
SIGN-mediated infection in trans at levels comparable to 
the inhibition shown in cis. These glycodendritic polymers 
were the first example of a multivalent DC-SIGN antago-
nist describe in the literature.
After this proof of concept where sub micromolar 
apparent affinity and good antiviral activity have been 
reached presenting a simple carbohydrate (a mannose 
monosaccharide) as ligand for DC-SIGN, an improvement 
of these activities could be envisaged using more complex 
and specific carbohydrate ligands. Moreover, Boltorn hy-
perbranched dendritic polymers are polydisperse materials 
and the control of the synthesis and the reproducibility of 
biological assays could be compromised by the presence 
of a mixture of compounds. A monodisperse Boltorn type 
dendrimers and dendrons were prepared using a step-wise 
synthesis avoiding these potential problems. In this way, a 
new set of carbohydrate multivalent compounds were syn-
thesized using these monodisperse multivalent scaffolds.
From the point of view of the ligand moiety, it has 
been reported the design and synthesis of two glycomi-
metic compounds that bind to DC-SIGN. A pseudo-1,2-
mannobioside 1 (Figure 6), which contains a mannose unit 
FIGURE 5 - Boltorn hyperbranched structures of 2nd (BH20) and 3rd (BH30) generation and the glycodendrimer BH30sucMan.
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connected to a conformationally locked cyclohexanediol 
to mimic 1,2-mannobioside (Mana (1,2)Man) (Reina et 
al., 2007). The pseudo-trisaccharide 2 mimicking the 
linear Mana (1,2)Mana (1,6)Man trisaccharide of the D3 
arm of Man9, (Figure 6) was designed following the same 
concept (Mari et al., 2007). The affinity for DC-SIGN of 
both monovalent ligands was too weak (mM range) to be 
considered as effective inhibitors of DC-SIGN-mediated 
infections and their therapeutic potential was limited. 
However, this low affinity could be overcome when li-
gands were presented in a multimeric form.
The multivalent presentation of glycomimetics 1 
and 2 was achieved by conjugation of the monovalent 
ligands to tetra- and multivalent scaffolds based on Bis-
FIGURE 6 – pseudo-disaccharide 1 and pseudo-trisaccharide 2.
MPA as building block to generate dendritic compounds 
with Boltorn-type structures. Two scaffolds with different 
valency were synthesized: a tetravalent dendron and a 3rd 
generation Boltorn-type dendrimer, both being monodis-
perse compounds. The corresponding tetravalent glyco-
dendrons 3 and 4, and the multivalent glycodendrimers 5 
and 6 (Figure 7) were evaluated as potential inhibitors of 
DC-SIGN (Sattin et al., 2010).
The tetravalent dendron 4 with four copies of 
pseudo-trisaccharide 2 was shown to inhibit the trans in-
fection of T lymphocytes by HIV. Infection was abrogated 
almost totally by 4 at 100 mM concentration, and an IC50 
ca. 10 mM could be estimated (Sattin et al., 2010), a very 
promising value as starting point to define better antiviral 
compounds. Furthermore, dendron 4 was evaluated as a 
suitable candidate for the development as topical HIV mi-
crobicide (Berzi et al., 2012). This compound was tested as 
inhibitor in an experimental model based on HIV infection 
of explant tissues taken from human uterine cervix. This 
experiment was the previous step to test the inhibitors in in 
vivo models. It was demonstrated that dendron 4 inhibited 
80-90% of cervical explant HIV infection.
Additionally, the tetra- and multivalent systems 
were tested in vitro using an infection model based on 
pseudotyped viral particles with the Ebola virus envelope 
glycoprotein GP1. In these experiments, the tetravalent 
FIGURE 7 - Structure of tetravalent glycodendrons 3 and 4 and glycodendrimers 5 and 6.
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systems 3 and 4 were very active in the low micromolar 
range, and the multivalent systems 5 and 6 showed a very 
strong inhibition effect with IC50 in the nanomolar range 
(Luczkowiak et al., 2011).
Glycodendritic systems based on the Cu (I) 
catalyzed azide-alkyne cycloaddition (CuAAC)
In the previous section, it has been described an ap-
proach to create carbohydrates multivalent systems based 
on Boltorn type structures. The synthesis of these kinds 
of polyesters-based glycodendrons and glycodendrimers 
presented some disadvantages. The divergent synthetic 
approach entailed the attachment of the saccharidic units 
to the multivalent scaffold in the last stage, generating 
several covalent bonds simultaneously in a single syn-
thetic step. For this reason, this approach can generate 
structural defects due to an incomplete conjugation giving 
rise to molecules with similar structure, and physical and 
chemical properties and therefore, being very difficult the 
purification step to get pure and monodisperse glycoden-
drimers. A more efficient strategy should be addressed to 
achieve the preparation of this kind of molecules.
In this context, our group designed new multivalent 
systems based on a convergent strategy using a very effi-
cient type of click reaction (Kolb, Finn, Sharples, 2001), in 
particular, the Cu(I) catalyzed azide-alkyne cycloaddition 
(CuAAC) (Rostovtsev et al., 2002; Tornøe, Christensen, 
Medal, 2002), as an alternative to the preparation of 
glycodendrons and glycodendrimer. The click chemistry 
reaction CuAAC is a very efficient, versatile, and popu-
lar reaction that has found several applications in many 
fields to achieve the preparation of very diverse molecules 
ranging from small compounds to polymers, hydrogel 
and other larges entities, including dendrimers (Wu et 
al., 2004; Joralemon et al., 2005; Malkoch et al., 2005; 
Fernández-Megia et al., 2006; Franc, Kakkar, 2010). Fol-
lowing a convergent strategy based on CuAAC reaction, 
the synthesis of a new class of glycodendrons with full 
control of the structure was developed. In the new design, 
it was considered the presence at the focal position of an 
appropriated functional group permitting the conjugation 
of biomolecules of interest (peptides, nucleic acids, etc.) 
using again a CuAAC reaction. Glycodendrons, contain-
ing up to nine copies of carbohydrate ligands (mannose or 
fucose) (Figure 8), showed an efficient binding with the 
DC-SIGN receptor at the surface of DCs (Ribeiro-Viana et 
al., 2012). The functional group at the focal position was 
used to conjugate a fluorophore (a BODIPY derivative) to 
study the DC-SIGN-mediated internalization of these gly-
codendrons after the binding event at the surface of DCs.
These glycodendrons internalized efficiently into 
monocyte derived DCs in a receptor-dependent manner 
as it was demonstrated using imaging flow cytometry. 
Additional experiments performed to determine the in-
tercellular routing of these molecules into DCs showed 
that glycodendrons were co-localized within lysosomes. 
Finally, it was evaluated the capacity of glycodendrons to 
induce the maturation of DCs. None of the glycodendron 
showed any activity to induce DCs maturation neither ex-
pression of cytokines at the concentration tested. Besides 
this fact, they can be considered as interesting vectors to 
internalize into target cells biomolecules of interest such 
as immunogenic peptides, conjugated to the focal position 
of these glycodendrons, opening the door for their use to 
develop synthetic vaccines.
This convergent click chemistry approach to prepare 
glycodendritic structures could be applied to different 
scaffolds generating interesting carbohydrate multivalent 
systems.
Glycodendrofullerenes
Fullerene could be a very attractive core with a 
rigid spherical shape for a unique globular carbohydrate 
multivalent presentation. However, its low solubility in 
polar solvents is one of the major drawbacks to address 
the preparation of biological active compounds. On the 
other hand, fullerenes allow the possibility to functional-
ize its 3D structure in different positions of the C60 cage 
in a controlled fashion. Initially, the approaches reported 
in the literature to synthesize fullerenes derivatives bear-
ing carbohydrates were based on a mono-addition pattern 
(Nishida et al., 2004; Enes et al. 2005) on the fullerene 
sphere or on a “one side” multi-addition pattern (Cardullo 
et al., 1998; Ito et al., 2003; Kato et al., 2005; Isobe et al., 
2007). In all these cases, fullerene derivatives showed an 
amphiphilic character with the fullerene being the lipophilic 
part of the structures. Recently, it has been shown that this 
amphiphilic character of sugar fullerene conjugates can be 
avoided by obtaining hexakis-adducts of [60]fullerene in 
which the C60 sphere could be completely surrounded by 
the sugar moieties (mannose, glucose, galactose or fucose) 
in a T-symmetrical octahedral addition pattern (Nieren-
garten et al., 2010). The conjugation of sugar residues to 
an alkyne-substituted Bingel-Hirsch hexakis-adducts was 
performed by employing the CuACC methodology. So, it 
was obtained the first example of a globular polytopic ligand 
named glycofulleres or “sugar balls” (Figure 9).
To increase the valency of these systems, a divalent 
dendron with mannose was used to obtain the first glyco-
dendrofullerene with 24 sugars moieties on the periphery 
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FIGURE 8 - Mannosyl nonavalent dendron fluorescence labeled with BODIPY.
of C60 (Sánchez-Navarro et al., 2011) (Figure 9). These 
compounds were water soluble and interact with Con-
canavalin A in a multivalent manner demonstrating the 
accessibility of the sugars on the fullerene surface to be 
recognized by a lectin. Moreover, the compounds showed 
a good stability and low toxicity which confirmed the ap-
propriate features to be used in cellular assays.
Globular glycofullerenes with higher valency were 
prepared by a convergent strategy combining trimannosyl-
ated glycodendrons with a Bingel-Hirsch hexakis-adduct 
[60]fullerene to obtain glycodendrofullerenes with 36 
mannoses (Figure 9) and two different spacers. Also, it was 
introduced for the first time the biological activity of these 
compounds in a cellular infection model providing impor-
tant information about the potential use of these new gly-
comimetics as viral inhibitors. These glycodendrofuller-
enes act as antiviral agents in a DC-SIGN dependent Ebola 
pseudotype infection model (Luczkowiak et al., 2013). 
Glycofullerene with 12 mannoses showed an IC50 of 2 mM, 
a very promising data; however, an unexpected result was 
obtained for the activity of the glycodendrofullerene with 
36 mannoses. The increase of valency induced a loss of 
antiviral effect (IC50 c.a. 70 mM). This could be probably 
related to the steric congestion of sugars at the surface of 
fullerene. Furthermore, one important factor to achieve 
high affinity in binding processes was not only the spatial 
presentation of ligands but also the adequate accessibility 
of these ligands to interact with the receptor, DC-SIGN 
in this case. Using a glycodendrofullerene with 32 man-
nose (same valency) but including a longer spacer, was 
observed a remarkably increase of the inhibitory activity 
of this compound (IC50 0.3 mM), probably due to a more 
efficient interaction of the mannose ligand with DC-SIGN. 
This result highlights the importance to combine an ad-
equate scaffold to achieve the multivalency (the spherical 
fullerene) with the right ligand accessibility and flexibility. 
The valency of the compound is an important factor to 
obtain good affinities in a carbohydrate-lectin interaction 
but as it has been shown in these assays, it is not the only 
factor to be taken into account. Based on these results, 
fullerenes appear as very attractive scaffolds for a globular 
multivalent presentation of sugars.
J. J. Reina, J. Rojo118
FIGURE 9 - Glycofullerenes with 12, 24 and 36 mannoses.
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Virus-like glycodendrinanoparticles
Despite their elegant design, none of the artificial 
carbohydrates multivalent systems described (including 
the glycodendrofullerenes) have achieved the size and the 
valency to mimic properly natural systems implicated in 
DC-SIGN dependent infection processes such as viruses or 
other pathogens while maintaining full control of shape and 
structure. In the particular cases of glycodendritic structures, 
valency up to 100 are very rare and, in most of the cases, 
without full control of shape. Recently, a novel strategy of 
“nested polyvalency” was reported to achieve a controlled 
design of highly polyvalent glycodendriproteins. This ap-
proach was performed through the multivalent assembly 
of protein monomers themselves carrying polyvalent 
glycan display motifs (glycodendrons) (Ribeiro-Viana et 
al., 2012a). These synthetic protein assemblies display the 
highest known number of glycans (n = 1620) yet presented 
in a homogeneous manner (Figure 10). To perform the 
construction of glycodendriprotein nanoparticles trying to 
mimic the display in target pathogens, the self-assembled 
protein sphere-like icosahedron Qb (Kozlovska et al., 1993) 
was used. The monomer of this protein can assemble into 
a 180 copy multimer. Using a tag-and modify strategy 
(Chalker, Bernardes, Davis, 2011), a non-natural alkyne 
containing amino acid (tag), the L-homopropargyl glycine 
(Hpg), was introduced in the Qb monomer. This tag was 
used for the attachment of glycodendrons with three and 
nine mannose units appropriately functionalized at the focal 
position with and azide group. The well-defined polyvalent 
glycoprotein assemblies presenting on their surface 1620 
copies of mannose was tested in the DC-SIGN dependent 
Ebola pseudotype infection model.
The glycoprotein particles showed exciting antivi-
ral activity, preventing dendritic cells infection by Ebola 
pseudotyped virus through competitive blockage of the 
DC-SIGN receptor in the nanomolar to picomolar range 
(Ribeiro-Viana et al., 2012a). This result clearly indicates 
the efficiency of these systems to interact with this pattern 
recognition receptor and to compete with pathogens during 
their entry into target cells.
CONCLUSIONS
The field of dendrimers is in its maturity and many 
achievements and goals have been reached since the first 
publication describing the synthesis of a dendritic molecule 
in 1978 (Buhleier, Wehner, Vögtle, 1978). One of the most 
FIGURE 10 - Qb particle bearing 1620 mannose units.
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interesting areas of research where dendrimers start to have 
an important contribution is nanomedicine. Taking advan-
tage of the possibilities that offer the dendritic structures and 
the opportunities to combine biomolecules or any kind of 
ligands with these platforms for a multivalent presentation, 
many different applications have been described for these 
so beautiful and interesting molecules. The combination of 
carbohydrates with dendrimers allows the creation of glyco-
dendrimers, very powerful tools to be exploited in the field 
of glycoscience mimicking the presentation of carbohy-
drates in nature. DC-SIGN, a very important and attractive 
receptor with relevant biological implications, has been one 
of the targets for these glycodendrimers. Several examples 
have been described in the literature that demonstrate the 
potential applications of glycodendritic structures to interact 
efficiently with DC-SIGN inhibiting infection processes 
mediated by this lectin. From these examples, important 
lessons came out respect to the necessary relevant issues to 
have access to effective glycodendritic molecules. Efficient 
chemistries, valency, size, spatial presentation, flexibility 
and accessibility of the ligands are among the important is-
sues to be considered. Still, much work remains be done in 
the near future and novel scaffolds for multivalent presenta-
tions will be explored to achieve new goals and applications.
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